Search

Objective To evaluate the risk of recurrence or metastasis of breast cancer by LNG-IUS via meta-analysis. Methods We searched literature in the PubMed, Web of Science, Cochrane, EMBASE, CBM, CNKI, VIP, and WanFang database.The retrieval period was from January 2014 to October 2021.Data extraction and quality evaluation were conducted for the included randomized controlled study (RCT) to analyze whether LNG-IUS can increase the risk of recurrence or metastasis of breast cancer. Results A total of 1309 Chinese and English studies were retrieved; 5 RCTs were included in this study, and 446 patients were enrolled.The combined total effect value in the fixed-effect model with RD (95%CI)0.03(-0.03-0.08), Z=1.05, P=0.29) indicated that the LNG-IUS+tamoxifen group did not increase the risk of recurrence or metastasis of breast cancer compared with the tamoxifen group.The funnel diagram was basically symmetrical, suggesting that the publication bias was small. Conclusion Wearing the LNG-IUS does not increase the risk of relapse or metastasis of breast cancer significantly, and it provides certain safety for patients with breast cancer.

Objective To evaluate the risk of recurrence or metastasis of breast cancer by LNG-IUS via meta-analysis. Methods We searched literature in the PubMed, Web of Science, Cochrane, EMBASE, CBM, CNKI, VIP, and WanFang database. The retrieval period was from January 2014 to October 2021. Data extraction and quality evaluation were conducted for the included randomized controlled study (RCT) to analyze whether LNG-IUS can increase the risk of recurrence or metastasis of breast cancer. Results A total of 1309 Chinese and English studies were retrieved; 5 RCTs were included in this study, and 446 patients were enrolled. The combined total effect value in the fixed-effect model with RD (95%CI) 0.03(-0.03-0.08), Z=1.05, P=0.29) indicated that the LNG-IUS+tamoxifen group did not increase the risk of recurrence or metastasis of breast cancer compared with the tamoxifen group. The funnel diagram was basically symmetrical, suggesting that the publication bias was small. Conclusion Wearing the LNG-IUS does not increase the risk of relapse or metastasis of breast cancer significantly, and it provides certain safety for patients with breast cancer. [ABSTRACT FROM AUTHOR]

目的调查分析放置左快诺孕酮宫内缓释系统( LNG-IUS) 患者的取出原因及放置时间。方法收集 2014 年1 月～ 2018 年12 月于我院放置LNG-IUS 的女性患者1 632 例， 其中失访病例154 例， 最终纳入1 478 例。 记录每一年LNG-IUS 取出情况，不同放置指征患者的LNG-IUS 取出情况以及LNG-IUS 取出原因、放置时间。结果 在放置LNG-IUS 的1 478 例患者中，共取出106 例(7. 2% ） 。2014 ~2018 年LNG-IUS 分别取出8 例( 15. 1% ） 、13 例(6. 6% ） 、17 例( 5. 8% ） 、32 例( 7. 7% ） 、36 例( 7. 0% ） 。在放置LNG-IUS 的患者中， 避孕202 例， 取出38 例 ( 18. 8% ） ； 冶疗子宫腺肌症968 例，取出51 例(5. 3% ） ； 冶疗子宫内膜息肉191 例，取出11 例(5. 8% ） ； 冶疗子宫内 膜病变101 例，取出5 例(5. 0% ） ； 冶疗子宫肌瘤16 例，取出1 例(6. 3% ） 。LNG-IUS 取出106 例患者中，取出原因 为阴道不规则流血19 例( 17. 9% ） 、LNG-IUS 下移13 例( 12. 3% ） 、闭经11 例( 10. 4% ） 、腰痛8 例(7. 6% ） 、月经量 减少4 例( 3. 8% ） 、LNG-IUS 到期及超期25 例( 23. 6% ） 、因计划妊娠取出15 例( 14. 2% ） 、其他原因11 例 ( 10. 4% ） 。LNG-IUS 放置时间, ≤ 1年46 例(43.4% ） 、> 1 ~2 年26 例(24. 5% ） 、>2 ~ 3 年6 例(5. 7% ) 、＞ 3 ~4 年 3 例(2. 8% ） 、＞5 年25 例(23. 6% ） 。结论导致LNG-IUS 取出的主要原因是阴道不规则流血、LNG-IUS 下移及闭 经，取出时间多在放置LNG-IUS 后2 年内。 [ABSTRACT FROM AUTHOR]

Copyright of Practical Pharmacy & Clinical Remedies is the property of Editorial Department of Practical Pharmacy & Clinical Remedies and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)